Pre-Assessment

Name
Which of the following best represents your profession?
What is your primary specialty?
1a. Which of the following best describes the shared biochemical mechanisms that contribute to the development of obesity-related comorbidities such as MASLD, CVD, and T2D?
1b. Please select the extent to which you feel confident in your answer.
Completely confidentFairly confidentSomewhat confidentSlightly confidentNot confident
Completely confident
Fairly confident
Somewhat confident
Slightly confident
Not confident
2a. A patient with obesity and a history of frequent antibiotic use for acne presents with mild hepatic steatosis and early fibrosis on imaging. ALT is normal. She follows a high-sugar, low-fiber diet and exercises minimally. What would you consider next as a key contributor to her fibrosis?
2b. Please select the extent to which you feel confident in your answer.
Completely confidentFairly confidentSomewhat confidentSlightly confidentNot confident
Completely confident
Fairly confident
Somewhat confident
Slightly confident
Not confident
3a. Which non-invasive test is most appropriate for initial risk assessment of MASLD/MASH in a patient with obesity?
3b. Please select the extent to which you feel confident in your answer.
Completely confidentFairly confidentSomewhat confidentSlightly confidentNot confident
Completely confident
Fairly confident
Somewhat confident
Slightly confident
Not confident
4a. You are assessing a 60-year-old man with obesity and elevated ALT whose initial FIB-4 score is 1.8. What is the most appropriate next step in evaluation?
4b. Please select the extent to which you feel confident in your answer.
Completely confidentFairly confidentSomewhat confidentSlightly confidentNot confident
Completely confident
Fairly confident
Somewhat confident
Slightly confident
Not confident
5a. Which of the following mechanisms best explains how GLP-1 receptor agonists improve outcomes in MASLD/MASH?
5b. Please select the extent to which you feel confident in your answer.
Completely confidentFairly confidentSomewhat confidentSlightly confidentNot confident
Completely confident
Fairly confident
Somewhat confident
Slightly confident
Not confident
6a. A 58-year-old man with obesity (BMI 34 kg/m²), type 2 diabetes, and early chronic kidney disease (eGFR 58 mL/min/1.73 m²) is being considered for therapy with an investigational dual glucagon GLP-1 receptor agonist. If used, which of the following clinical outcomes would most likely occur?
6b. Please select the extent to which you feel confident in your answer.
Completely confidentFairly confidentSomewhat confidentSlightly confidentNot confident
Completely confident
Fairly confident
Somewhat confident
Slightly confident
Not confident
7. How confident are you in your ability to assess, screen for, and manage patients with obesity and associated MASLD/MASH using current evidence-based approaches
Scroll to Top